Breaking News
The Government's Secret Plan For America's Collapse | Annie Jacobsen
The TRUTH About Filling Raised Garden Beds With Logs...
Andy Schectman: "Prepare For Collapse..." | Silver Price Predictions
Felix Nikolas Prehn: A Generational Financial Reset Is Here
Top Tech News
Most artificial limbs rely on silicone or plastic to mimic human hands.
Flying cell tower beams phone signal to Japan from 10 miles up
Chinese Commercial Reactor Achieves Nuclear Fusion with Clean Hydrogen-Boron Fuel
Med Beds Just Took a MASSIVE Step Forward, Healing People in Days!
Palmer Luckey: Autonomous Weapons Are Ancient and Why Anduril Won't Build Humanoids | EP #295
A laser just photographed objects through six feet of concrete
Elon Musk's Next-Gen Motor Destroy Entire EV Industry
China's disputed satellite refueling heralds new space war era
BYD Will Put Solid-State Batteries In An EV Next Year: Executive
FDA-cleared exoskeleton puts spinal-cord patients back on their feet
Experimental cancer drug that targets common genetic fault can shrink tumours...
An experimental cancer drug that targets a common genetic fault has been shown to shrink tumours by up to 67 per cent in just six weeks.
Scientists tested their newly developed anti-cancer drug AMG 510 on four patients, two of whom saw their tumours shrink. It did not work for the others.
In studies on mice, the treatment helped to shrink, and in some cases eradicate, the growing tumours.
The daily pill works by turning 'off' the KRAS gene. Mutated forms of the genes are permanently trapped 'on', causing cancerous cells to multiply.
This abnormal activity fuels the development of up to 50 per cent of lung cancers, as well as some pancreatic and bowel cancers.
The pharmaceutical company described their findings as a 'milestone' for patients with cancer KRAS-mutant cancers.
The research was led by by pharmaceutical company Amgen Research, based in Thousand Oaks, California.
The findings, published in Nature, are the first to report the effects of inhibiting KRAS with a drug.